Table 1 Patients’ baseline characteristics

Patient number

62

Age (years)

33.1 ± 10.3

Gender (male)

74.2 % (46/72)

Disease duration (months)

96.0 (0.0–480.0)

Disease duration < 2 years

32.3 % (20/62)

Disease location

 Ileo

14.5 % (9/62)

 Ileocolonic

74.2 % (46/62)

 Colonic

11.3 % (7/62)

Surgery required

62.9 % (39/63)

Extra fistula

34.4 % (21/61)

Intra fistula

8.2 % (5/61)

Perianal disease

48.4 % (30/62)

Smoking

17.3 % (9/52)

Concomitant use

 5-Aminosalicylates

91.9 % (57/62)

 Steroids

9.7 % (6/62)

 Immunomodulators

24.2 % (15/62)

 Elemental diet

62.9 % (39/62)

IFX experience

 Experience with IFX

53.2 % (33/62)

 Double dose

33.3 % (11/33)

 Duration of IFX use (months)

19.0 (1.0–100)

 Reason for switching

  PNR

6.3 % (2/32)

  SNR

46.9 % (15/32)

  Intolerance

43.8 % (14/32)

  Others

3.1 % (1/32)

Baseline CDAI (points)

185.1 ± 76.4

Baseline CRP (mg/dL)

0.74 (0.00–6.86)